Stereotaxis Inc (STXS) Stock Forecast & Price Target

Stereotaxis is viewed favorably because its recurring revenue is gaining traction, with $6.2 million in 2Q26 rising 7.5% year over year and over $1 million in robotic catheter sales, signaling that the higher-margin disposables and accessories stream is beginning to offset product-transition headwinds. The company also appears to be nearing a commercial inflection point, as regulatory approvals for GenesisX, MAGiC ablation, and Synchrony have started converting into early sales momentum, while management expects further sequential improvements in 3Q and 4Q and cash flow profitability in 1H27. Although 2Q26 system revenue fell to $1.5 million with no robotic systems placed, the first U.S. GenesisX purchase, early Synchrony sales, and expanding catheter production capacity support a stronger outlook for 2027 and beyond.

Stereotaxis is facing a fundamentally कमजोर demand and execution profile, with 1Q revenue of $6.3M and Q2 revenue of $7.7M both missing expectations as system sales fell sharply and no robotic system deliveries were made in Q2. Its updated 2026 revenue estimate of $34.5M and 2027 estimate of $47.0M still imply dependence on a volatile mix of $8.3M system sales versus $26.1M recurring revenue in 2026, while high operating expenses and continuing net losses suggest limited operating leverage. Cash-flow risk, supply constraints on MAGiC, possible delays in product adoption and regulatory timing, and reliance on capital raises and key leadership all reinforce a cautious, negative fundamental outlook.